MarketPulse
M

$MREO

28 articles found
0 positive
28 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Suit Over Undisclosed Drug Safety Risks

Rosen Law Firm alerts $SLNO investors about class action lawsuit alleging false statements regarding DCCR drug safety. Lead plaintiff deadline: May 5, 2026.
MREOCOTYSLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 clinical trials. Investors can join by April 6, 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Mereo BioPharma Stock Collapses 88% on Failed Trials; Class Action Lawsuit Filed

Pomerantz Law Firm files securities fraud lawsuit against $MREO after failed Phase 3 trials tank stock 87.7%. Lead Plaintiff deadline: April 6, 2026.
MREORAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials, $MREO Investors Urged to Act

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC; investors in $MREO securities from June 2023-December 2025 urged to act by April 6, 2026 deadline.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials and Investor Losses

Mereo BioPharma faces class action lawsuit alleging misrepresentations regarding failed Phase 3 clinical trials, with lead plaintiff deadline April 6, 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Four Companies Face Shareholder Lawsuits Over Alleged Disclosure Failures

Law firm Holzer & Holzer announces April 6, 2026 lead plaintiff deadlines for class actions against TCPC, MREO, POM, and RARE over alleged material misstatements.
TCPCMREORAREPOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Investors Face April Deadline in Setrusumab Securities Lawsuit

Rosen Law Firm urges MREO investors to act before April 6, 2026 deadline in securities class action alleging misleading clinical trial statements.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials, Alleged Investor Deception

Mereo BioPharma faces class action lawsuit alleging false statements about failed Phase 3 trials ORBIT and COSMIC. Investors from June 2023-December 2025 eligible; lead plaintiff deadline April 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Holzer & Holzer, Llc

Four Companies Face Shareholder Lawsuits Over Alleged Disclosure Failures

Four companies face April 6, 2026 lead plaintiff deadline in shareholder lawsuits alleging disclosure violations involving valuations, clinical trials, and fraudulent promotion.
TCPCMREORAREPOMsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Failed Drug Trial Disclosures

Rosen Law Firm urges MREO investors to join class action over alleged misleading statements regarding setrusumab Phase 3 trial failures.
MREOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Clinical Trials and Investor Losses

Class action lawsuit filed against Mereo BioPharma over alleged misstatements regarding failed Phase 3 clinical trials. Investors have until April 6, 2026, to join.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Mereo BioPharma Stock Collapsed 87.7% After Trial Failure; Class Action Deadline Looms

Pomerantz Law Firm filed class action against $MREO after Phase 3 trial failures. Stock plummeted 87.7%. Investor deadline: April 6, 2026.
NAVNSNOWMREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Faces Class Action Over Failed Drug Trials and Misleading Statements

Mereo BioPharma faces class action over failed Phase 3 trials and alleged misleading statements. Investor deadline April 6, 2026.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Biotech Giants Face Class Action Suits After Failed Bone-Disease Trials Crater Stock Prices

Class action suits filed against Ultragenyx and Mereo BioPharma following failed Phase III trials for setrusumab, with stock prices crashing 42.32% and 87.7% respectively.
MREORAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Misleading Clinical Trial Disclosures

Investors in $MREO have until April 6, 2026 to join securities class action alleging misleading statements about failed Phase 3 setrusumab trials.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Mereo BioPharma Hit With Class Action Over Failed Clinical Trials and Misleading Statements

Class action filed against Mereo BioPharma over allegedly false statements regarding failed Phase 3 clinical trials, covering $MREO investors from June 2023 to December 2025.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Lawsuit Over Setrusumab Trial Failures

Securities class action filed against $MREO for allegedly misleading investors about Phase 3 clinical trial results. Lead plaintiff deadline April 6, 2026.
MREOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Enphase Energy Faces Securities Class Action Over Inventory Claims

Rosen Law Firm filed securities class action against Enphase Energy ($ENPH) alleging false statements on inventory management and tax credit impacts. Lead plaintiff deadline April 20, 2026.
LAKEMREOENPHsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Mereo BioPharma Faces Class Action Over Failed Drug Trials; Stock Crashes 87.7%

Robbins LLP sues Mereo BioPharma over setrusumab trial failures; stock crashes 87.7% to $0.29 after December 29 announcement.
MREOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Mereo BioPharma Faces Securities Class Action Over Setrusumab Trial Failures

Mereo BioPharma faces securities class action for allegedly concealing failed Phase 3 trials for setrusumab. Investors have until April 6, 2026 to act.
MREOsecurities class actionmisleading statements